Zobrazeno 1 - 10
of 1 317
pro vyhledávání: ''
Autor:
Natalie T. Mills, Hikaru Hori, Scott R. Clark, Célia Fourrier, Bernhard T. Baune, Jennie Louise, K Oliver Schubert, Emma Sampson
Publikováno v:
European Neuropsychopharmacology. 53:34-46
Given the role of low-grade inflammation in the pathophysiology of major depressive disorder (MDD), anti-inflammatory strategies may improve treatment outcomes in some patients. However, it is controversial whether they can be used as adjunctive trea
Autor:
Christiane Mühle, Valery Grinevich, Johannes Kornhuber, Patrick Bach, Christian Weinland, Falk Kiefer, Bernd Lenz, Iulia Zoicas
Publikováno v:
European Neuropsychopharmacology. 51:55-67
Alcohol use disorder (AUD) is a severe illness, for which we lack sufficient mechanistic understanding. Preliminary evidence associates AUD with the oxytocin (OXT) system. Here we investigated alterations in endogenous OXT blood concentrations in pat
Autor:
Claudia da Costa Leite, Márcio Gerhardt Soeiro-de-Souza, E. Scotti-Muzzi, Fernando Fernandes, Rodrigo Machado-Vieira, R. T. De Sousa, Maria Concepcion Garcia Otaduy
Publikováno v:
European Neuropsychopharmacology. 49:93-100
The diagnosis and treatment of bipolar depression (BDep) poses complex clinical challenges for psychiatry. Proton magnetic resonance spectroscopy (1H-MRS) is a useful imaging tool for investigating in vivo levels of brain neuro-metabolites, critical
Autor:
Thomas Habekost, Julijana le Sommer, Birte Glenthøj, Signe Vangkilde, Bob Oranje, Birgitte Fagerlund, Jens Richardt Møllegaard Jepsen, Ann-Marie Low
Publikováno v:
European Neuropsychopharmacology. 46:83-92
Deficient information processing in ADHD theoretically results in sensory overload, which in turn may underlie its symptoms. If this sensory overload is caused by deficient filtering of environmental stimuli, then one would expect finding deficits in
Autor:
Martijn Arns, A. John Rush, Michel J.A.M. van Putten, Madelon A. Vollebregt, Nikita van der Vinne, Michiel Eebes
Publikováno v:
European neuropsychopharmacology, 44, 14-22. Elsevier
European Neuropsychopharmacology, 44, 14-22. Elsevier
European Neuropsychopharmacology, 44, 14-22. Elsevier
Using pre-treatment biomarkers to guide patients to the preferred antidepressant medication treatment could be a promising approach to enhance its current modest response and remission rates. This open-label prospective study assessed the feasibility
Autor:
E. Sherwood Brown, Collette Bice, Alyson Nakamura, Jayme M. Palka, Elena I. Ivleva, Zena Patel, Meagan McArdle, Markey C. McNutt, Shane Tipton, Traci Holmes
Publikováno v:
European Neuropsychopharmacology. 43:92-101
Bipolar disorder is associated with high rates of alcohol use disorder. However, little is known about the treatment of this dual diagnosis population. Previous studies suggest that ondansetron decreases alcohol use, particularly in people with speci
Autor:
Michele Verde-Ramo Soares, Alana Gomes de Souza, Adriano José Maia Chaves Filho, Danielle Silveira Macêdo, Tatiana de Queiroz, Paloma Marinho Jucá, Natássia Lopes Cunha, Carolina Horta Andrade, Dino César da Silva Clemente, Melina Mottin, Christina Alves Peixoto, Patrícia de Araújo Rodrigues
Publikováno v:
European Neuropsychopharmacology. 42:57-74
Immune-inflammatory mechanisms are involved in the pathophysiology of bipolar disorder. Tetracyclines present neuroprotective actions based on their anti-inflammatory and microglia suppressant effects. Doxycycline (DOXY) is a tetracycline that demons
Autor:
Nídia Fernandez Ros, Elham Jaberi, Brice Ozenne, Kristian Linnet, Shohreh Issazadeh-Navikas, Hanne D. Hansen, Lene Lundgaard Donovan, Sys Stybe Johansen, Gitte M. Knudsen, Jens Vilstrup Johansen
Publikováno v:
European Neuropsychopharmacology. 42:1-11
Psilocybin has in some studies shown promise as treatment of major depressive disorder and psilocybin therapy was in 2019 twice designated as breakthrough therapy by the U.S. Food and Drug Administration (FDA). A very particular feature is that inges
Publikováno v:
European Neuropsychopharmacology. 41:63-69
Clozapine is the only antipsychotic compound indicated for refractory-schizophrenia. However, it is associated with emergent metabolic dysregulation and cardiovascular risk which may lead to mortality. In this study we aimed to explore predictors for
Autor:
Maya Amitai, Maya Lebow, Silvana Fennig, Michal Taler, Alan Apter, Alon Chen, Reut Ben-Baruch, Abraham Weizman
Publikováno v:
European Neuropsychopharmacology. 40:61-69
Major depressive disorder (MDD) is associated with alterations in circulatory cytokines, in adults as well as in children and adolescents. Administration of selective serotonin reuptake inhibitors (SSRIs) to MDD pediatric patients modifies cytokine l